drugset
drugset / Trial / NCT03801733

Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin

NCT03801733 ↗

Phase 1 Completed 134 enrolled Akebia Therapeutics
RandomizedSequentialOpen-labelBasic science

Summary

This is a Phase 1, three-part, open-label study to evaluate vadadustat as a perpetrator in drug-drug interactions with rosuvastatin, sulfasalazine, pravastatin, atorvastatin and simvastatin in healthy male and female subjects.

Timeline

Start
2018-06-17
Primary completion
2018-11-24
Completion
2018-11-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 40 mg Oral
Subject Pravastatin Small molecule 40 mg Oral
Subject Rosuvastatin Small molecule 20 mg Oral
Subject Simvastatin Small molecule 40 mg Oral
Subject Sulfasalazine Small molecule 500 mg Oral
Subject Vadadustat Small molecule 600 mg Oral

Indications

No indication recorded.